REGIONAL ANALYSIS OF A COHORT COMPASSIONATE-USE PROGRAM AND EARLY ACCESS PROGRAM WITH CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL

被引：0

作者：

Malik, Z. ^{[1
]}

di Lorenzo, G. ^{[2
]}

Bracarda, S. ^{[3
]}

Ardavanis, A. ^{[4
]}

Basaran, M. ^{[5
]}

Parente, P. ^{[6
]}

de Schultz, W. ^{[7
]}

Saad, F. ^{[8
]}

van Oort, I. ^{[9
]}

Gerritsen, W. R. ^{[9
]}

Aparicio, L. M. Anton ^{[10
]}

Matus, G. ^{[11
]}

Hitier, S. ^{[12
]}

Heidenreich, A. ^{[13
]}

Bahl, A. ^{[14
]}

机构：

[1] Clatterbridge Canc Ctr, Bebington, England

[2] Univ Naples Federico II, Naples, Italy

[3] ITT, Arezzo, Italy

[4] St Savas Anticanc Hosp, Athens, Greece

[5] Inst Oncol, Istanbul, Turkey

[6] Monash Univ, Fac Med, Melbourne, Vic 3004, Australia

[7] Urol Clin, Weissenfles, Germany

[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada

[9] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[10] Hosp Juan Canalejo, La Coruna, Spain

[11] Clin St Joseph, Liege, Belgium

[12] Sanofi, Chilly Mazarin, France

[13] Univ Hosp, Aachen, Germany

[14] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 11卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

111

引用

页码：37 / 37

页数：1

共 50 条

[1] Cohort compassionate-use program and early access program with cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: analysis by age group
Malik, Z.
Di Lorenzo, G.
Bracarda, S.
Ardavanis, A.
Basaran, M.
Parente, P.
De Schultz, W.
Saad, F.
Van Oort, I.
Gerritsen, W. R.
Anton Aparicio, L. M.
Matus, G.
Hitier, S.
Heidenreich, A.
Bahl, A.
BJU INTERNATIONAL, 2015, 115 : 61 - 62
[2] Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).
Malik, Zafar
di Lorenzo, Giuseppe
Bracarda, Sergio
Ardavanis, Alexandros
Basaran, Mert
Parente, Phillip
de Schultz, Wito
Saad, Fred
van Oort, Inge
Gerritsen, Winald R.
Aparicio, Luis M. Anton
Matus, Geoffrey
Hitier, Simon
Heidenreich, Axel
Bahl, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[3] Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel
Malik, Zafar I.
Di Lorenzo, Giuseppe
Basaran, Mert
Ardavanis, Alexandros
Parente, Phillip
de Schultz, Wito
Saad, Fred
van Oort, Inge
Gerritsen, Winald R.
Aparicio, Luis M. Anton
Matus, Geoffrey
Hitier, Simon
Heidenreich, Axel
Bahl, Amit
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[4] A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
Bavbek, Sevil E.
Malik, Zafar I.
Di Lorenzo, Giuseppe
Scholz, Hans-Jorg
van Oort, Inge M.
Siobhan Ng
Ozguroglu, Mustafa
Gerritsen, Winald R.
Mueller, Stefan
Marttila, Timo
Aparicio, Luis M. Anton
Albers, Peter
Gschwend, Juergen E.
Bensfia, Samira
Ecstein-Fraisse, Evelyne B.
Bracarda, Sergio
Heidenreich, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[5] A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
Bavbek, Sevil E.
Malik, Zafar
Di Lorenzo, Giuseppe
Scholz, Hans-Jorg
van Oort, Inge M.
Ng, Siobhan
Ozguroglu, Mustafa
Gerritsen, Winald R.
Mueller, Stefan
Marttila, Timo
Anton-Aparicio, Luis M.
Albers, Peter
Gschwend, Juergen
Bensfia, Samira
Ecstein-Fraisse, Evelyne B.
Bracarda, Sergio
Heidenreich, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
[6] REAL-WORLD USE OF CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: REGIONAL ANALYSIS
Parente, P.
Malik, Z.
di Lorenzo, G.
Bracarda, S.
Ardavanis, A.
Basaran, M.
de Schultz, W.
Saad, F.
van Oort, I.
Gerritsen, W. R.
Anton Aparicio, L. M.
Matus, G.
Hitier, S.
Heidenreich, A.
Bahl, A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 62 - 62
[7] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
Parente, P.
Malik, Z.
di Lorenzo, G.
Bracarda, S.
Ardavanis, A.
Basaran, M.
de Schultz, W.
Saad, F.
van Oort, I.
Gerritsen, W. R.
Anton Aparicio, L. M.
Matus, G.
Hitier, S.
Heidenreich, A.
Bahl, A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
[8] Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen - Interim Analysis Results From an Ongoing Compassionate-use Programme
Heidenreich, A.
Scholz, H. J.
van Oort, I.
Bavbek, S.
Mueller, S.
Ozguroglu, M.
Albers, P.
Gschwend, J.
Ecstein-Fraisse, E.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S498 - S498
[9] Updated safety results from a cohort compassionate-use programme (CUP) and early access programme (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D)
Malik, Z. I.
Di Lorenzo, G.
Ardavanis, A.
Basaran, M.
Parente, P.
De Schultz, W.
Saad, F.
Van Oort, I.
Hitier, S.
Heidenreich, A.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S697 - S697
[10] CABAZITAXEL (CBZ) plus PREDNISONE (P; CBZP) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (D): INTERIM RESULTS FROM COMPASSIONATE-USE PROGRAMME (CUP) AND EARLY-ACCESS PROGRAMME (EAP)
Malik, Z. I.
Di Lorenzo, G.
Basaran, M.
Parente, P.
de Schultz, W.
Gerritsen, W. R.
Anton Aparicio, L. M.
Hitier, S.
Heidenreich, A.
Bahl, A.
ANNALS OF ONCOLOGY, 2012, 23 : 306 - 307

← 1 2 3 4 5 →